Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
We examined the effect of intravenously infused glucagon-like peptide 1 (GLP-1) on subjective appetite sensations after an energy-fixed breakfast, and on spontaneous energy intake at an ad libitum lunch. 20 young, healthy, normal-weight men participated in a placebo-controlled, randomized, blinded, crossover study. Infusion (GLP-1, 50 pmol/ kg.h or saline) was started simultaneously with initiation of the test meals. Visual analogue scales were used to assess appetite sensations throughout the experiment and the palatability of the test meals. Blood was sampled throughout the day for analysis of plasma hormone and substrate levels. After the energy-fixed breakfast, GLP-1 infusion enhanced satiety and fullness compared with placebo (treatment effect: P < 0.03). Furthermore, spontaneous energy intake at the ad libitum lunch was reduced by 12% by GLP-1 infusion compared with saline (P = 0.002). Plasma GLP-1, insulin, glucagon, and blood glucose profiles were affected significantly by the treatment (P < 0.002). In conclusion, the results show that GLP-1 enhanced satiety and reduced energy intake and thus may play a physiological regulatory role in controlling appetite and energy intake in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 RA increase satiety, reduce food intake and delay gastric emptying whilst they also stimulate insulin release and inhibit glucagon secretion in a glucose-dependent manner (Fig. 1) [17, 18].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Short-term studies have demonstrated that glucagon-like peptide-1 receptor agonists (GLP-1RA) induce weight loss by promoting satiety and reducing hunger16–19.”
From Exploratory analysis of eating-and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment (2022) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, non-clinical and clinical studies have demonstrated increased satiety, reduced food intake and subsequent reductions in body weight following administration of GLP-1,7, 8”
From Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults (2014) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Among the two incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), the latter has been established as having therapeutic potential for reducing elevated plasma glucose (1, 2) and body weight (3), while the former has been unable to either stimulate insulin secretion (1) or lower plasma glucose effectively in type 2 diabetes (T2D) (4).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [3]
In the citing paper
“GLP-1 receptor agonists (GLP-1RA) have been shown to promote weight loss and decrease liver fat [28,29] (Figure 1).”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [29]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1975) · Journal of AOAC INTERNATIONAL · doi:10.1093/jaoac/58.5.1085 · Cited by 19,795
(1974) · Elsevier eBooks · doi:10.1016/b978-0-12-091304-6.x5001-0 · Cited by 6,755
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Self-citationTissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Self-citationInduction of intestinal epithelial proliferation by glucagon-like peptide 2.
Drucker, D. J., Erlich, P., Asa, S. L., & Brubaker, P. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7911 · Cited by 880
Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817
Self-citationScrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Mojsov, S., Heinrich, G., Wilson, I. B., Ravazzola, M., Orci, L., & Habener, J. F. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67324-7 · Cited by 724
Cited by
Items 101–200 of 1,003
Hormones and diet, but not body weight, control hypothalamic microglial activity
Gao, Y., Ottaway, N., Schriever, S. C., Legutko, B., García‐Cáceres, C., de la Fuente, E., Mergen, C., Bour, S., Thaler, J. P., Seeley, R. J., et al. (2014) · Glia · doi:10.1002/glia.22580 · Cited by 263
“…can be normalized, we tested whether hyperactivation of microglia also can be normalized with the glucagon-like peptide-1 agonist exendin-4 (Flint et al., 1998; Gutniak et al., 1992; Thorens Gao et al.: Hypothalamic Microglia in Obesity January 2014 21 et al., 1993) in DIO mice fed HFD for…”
BackgroundThe Protective Role of Butyrate against Obesity and Obesity-Related Diseases
Coppola, S., Avagliano, C., Calignano, A., & Berni Canani, R. (2021) · Molecules · doi:10.3390/molecules26030682 · Cited by 261
Tan, T. M., Field, B. C. T., McCullough, K. A., Troke, R. C., Chambers, E. S., Salem, V., Gonzalez Maffe, J., Baynes, K. C. R., De Silva, A., Viardot, A., et al. (2013) · Diabetes · doi:10.2337/db12-0797 · Cited by 258
“As GLP-1 suppresses appetite (6), patients generally experience weight loss with GLP-1 analog therapy (3).”
BackgroundLarsen, P. J., Fledelius, C., Knudsen, L. B., & Tang-Christensen, M. (2001) · Diabetes · doi:10.2337/diabetes.50.11.2530 · Cited by 257
Rüttimann, E. B., Arnold, M., Hillebrand, J. J., Geary, N., & Langhans, W. (2009) · Endocrinology · doi:10.1210/en.2008-1221 · Cited by 258
Sokos, G. G., Bolukoglu, H., German, J., Hentosz, T., Magovern, G. J., Maher, T. D., Dean, D. A., Bailey, S. H., Marrone, G., Benckart, D. H., et al. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.05.022 · Cited by 252
“Given that the peri-operative management was coordiated by the anesthesia and surgical teams, the following dditional data were collected to assess differences in perind postoperative management: (1) total intubation and inensive care time (in hours), (2) total doses of insulin and extrose infused, and (3) numbers and…”
BackgroundMethodMastication of almonds: effects of lipid bioaccessibility, appetite, and hormone response
Cassady, B. A., Hollis, J. H., Fulford, A. D., Considine, R. V., & Mattes, R. D. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.26669 · Cited by 251
“The lower and upper detection limits for the GLP-1 assay were 3.0 and 333 pmol/L, respectively, the intraassay CV was 29%, and the interassay CV was 10% at a sample concentration of 53 pmol/L.”
BackgroundInfluentialEffects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity
Maselli, D. B., & Camilleri, M. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_496 · Cited by 248
Jakubowicz, D., & Froy, O. (2013) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2012.07.008 · Cited by 246
“GLP-1 also slows gastric emptying leading to reduced appetite, increased satiety [51] and, as a result, weight loss [52].”
BackgroundFeltrin, K. L., Little, T. J., Meyer, J. H., Horowitz, M., Smout, A. J. P. M., Wishart, J., Pilichiewicz, A. N., Rades, T., Chapman, I. M., & Feinle-Bisset, C. (2004) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00039.2004 · Cited by 248
“In humans, intravenous infusions of both CCK (4, 18, 37, 39) and GLP-1 (2, 15, 21) inhibit energy intake and modulate gastrointestinal motility, consistent with the effects produced by C12.”
BackgroundIntegrated Upper Gastrointestinal Response to Food Intake
Camilleri, M. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.03.023 · Cited by 247
MacIntosh, C. G., Andrews, J. M., Jones, K. L., Wishart, J. M., Morris, H. A., Jansen, J. B., Morley, J. E., Horowitz, M., & Chapman, I. M. (1999) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/69.5.999 · Cited by 248
Hjerpsted, J. B., Flint, A., Brooks, A., Axelsen, M. B., Kvist, T., & Blundell, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13120 · Cited by 245
Self-citationAfferent signals regulating food intake
Bray, G. A. (2000) · Proceedings of the Nutrition Society · doi:10.1017/s0029665100000422 · Cited by 240
“Infusion of glucagon-like peptide-1 peripherally in human subjects will significantly reduce food intake (Flint et al. 1998).”
BackgroundDelgado-Aros, S., Kim, D.-Y., Burton, D. D., Thomforde, G. M., Stephens, D., Brinkmann, B. H., Vella, A., & Camilleri, M. (2002) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2002.282.3.g424 · Cited by 235
“GLP-1 decreases the feeling of hunger before meals and reduces food and fluid intake in healthy subjects (4, 8) and in diabetic (35) and nondiabetic (14) obese patients.”
BackgroundNauck, M. A., Petrie, J. R., Sesti, G., Mannucci, E., Courrèges, J.-P., Lindegaard, M. L., Jensen, C. B., & Atkin, S. L. (2016) · Diabetes Care · doi:10.2337/dc15-0165 · Cited by 233
Biologic actions and therapeutic potential of the proglucagon-derived peptides
Drucker, D. J. (2005) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0017 · Cited by 230
“GLP-1 also exerts potent effects on reduction of appetite, probably through direct and indirect effects on hypothalamic satiety centers and inhibition of gastric emptying”
BackgroundHarder, H., Nielsen, L., Thi, T. D. T., & Astrup, A. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.1915 · Cited by 232
Self-citationGlucagon-like peptide-1: From extract to agent. The Claude Bernard Lecture, 2005
Holst, J. J. (2006) · Diabetologia · doi:10.1007/s00125-005-0107-1 · Cited by 228
“In addition, GLP-1 was shown to inhibit appetite and food intake, both in healthy individuals [36], and in patients with type 2 diabetes [37].”
BackgroundSelf-citationGastric Inhibitory Polypeptide: the neglected incretin revisited
Meier, J. J., Nauck, M. A., Schmidt, W. E., & Gallwitz, B. (2002) · Regulatory Peptides · doi:10.1016/s0167-0115(02)00039-3 · Cited by 226
Beverage consumption, appetite, and energy intake: what did you expect?
Cassady, B. A., Considine, R. V., & Mattes, R. D. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.025437 · Cited by 229
Blonde, L., & Russell‐Jones, D. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01075.x · Cited by 227
MacIntosh, C., Morley, J. E., & Chapman, I. M. (2000) · Nutrition · doi:10.1016/s0899-9007(00)00405-6 · Cited by 219
Brown, E., Wilding, J. P. H., Barber, T. M., Alam, U., & Cuthbertson, D. J. (2019) · Obesity Reviews · doi:10.1111/obr.12841 · Cited by 222
“GLP‐1 is a physiological regulator of appetite and food intake via the central GLP‐1 receptors, mediating reduced appetite and weight loss.(67,68) Administration of GLP‐1 to rats into key mesolimbic structures (ventral segmental area and nucleus accumbens) resulted in decreased motivated behaviour for sucrose in rats,…”
BackgroundGLP-1 and energy balance: an integrated model of short-term and long-term control
Barrera, J. G., Sandoval, D. A., D'Alessio, D. A., & Seeley, R. J. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.77 · Cited by 220
“and similar satiating effects in response to exogenous GLP1R agonism have been observed in nonhuman primates and humans”
Peripheral Mechanisms in Appetite Regulation
Camilleri, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.09.016 · Cited by 214
A Human Cellular Model for Studying the Regulation of Glucagon-Like Peptide-1 Secretion
Reimer, R. A. (2001) · Endocrinology · doi:10.1210/en.142.10.4522 · Cited by 217
“through interactions with the hypothalamus (3, 4).”
BackgroundLoxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans
Beglinger, C., Degen, L., Matzinger, D., D'Amato, M., & Drewe, J. (2001) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.2001.280.4.r1149 · Cited by 216
Additional Protein Intake Limits Weight Regain after Weight Loss in Humans
Lejeune, M. P. G. M., Kovacs, E. M. R., & Westerterp-Plantenga, M. S. (2005) · British Journal of Nutrition · doi:10.1079/bjn20041305 · Cited by 211
“These shortterm effects may be related to increases in the concentrations of gut hormones, such as glucagon-like peptide-1 (Flint et al. 1998; Gutzwiller et al. 1999; Naslund et al. 1999) and cholecystokinin (Schick et al. 1991; Burton-Freeman et al. 2002; Kissileff et al. 2003).”
Backgroundon behalf of the NN8022-1807 Investigators, Lean, M. E. J., Carraro, R., Finer, N., Hartvig, H., Lindegaard, M. L., Rössner, S., Van Gaal, L., & Astrup, A. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.149 · Cited by 210
Self-citationGIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
Holst, J. J., & Rosenkilde, M. M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa327 · Cited by 207
“Another important difference is that GLP-1 inhibits appetite and food intake (5), resulting in weight loss upon chronic administration, whereas GIP generally is thought to have no effects on food intake (6).”
BackgroundSelf-citationA review of current guidelines for the treatment of obesity
(2022) · The American Journal of Managed Care · doi:10.37765/ajmc.2022.89292 · Cited by 207
Effect of proteins from different sources on body composition
Gilbert, J.-A., Bendsen, N. T., Tremblay, A., & Astrup, A. (2011) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2010.12.008 · Cited by 207
Self-citationRaun, K., von Voss, P., Gotfredsen, C. F., Golozoubova, V., Rolin, B., & Knudsen, L. B. (2007) · Diabetes · doi:10.2337/db06-0565 · Cited by 207
Ramasubbu, R., Taylor, V. H., Samaan, Z., Sockalingham, S., Li, M., Patten, S., Rodin, G., Schaffer, A., Beaulieu, S., & McIntyre, R. S. (2012) · Annals of Clinical Psychiatry · doi:10.1177/104012371202400110 · Cited by 206
Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes
Chapman, I., Parker, B., Doran, S., Feinle-Bisset, C., Wishart, J., Strobel, S., Wang, Y., Burns, C., Lush, C., Weyer, C., et al. (2005) · Diabetologia · doi:10.1007/s00125-005-1732-4 · Cited by 205
“Although differences in study design preclude the direct comparison of our results with those obtained with other peptide hormones, it is noteworthy that the magnitude of the reduction in food intake observed in response to pramlintide is similar to that reported for other gastrointestinal satiety signals, such as GLP…”
BackgroundResultGastric distension induces c-Fos in medullary GLP-1/2-containing neurons
Vrang, N., Phifer, C. B., Corkern, M. M., & Berthoud, H.-R. (2003) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00732.2002 · Cited by 204
“Additionally, peripheral GLP-1 has been shown to delay gastric emptying (30), and several groups have demonstrated appetite-suppressive effects of peripherally administered GLP-1 or GLP-1 agonists in humans (7, 10, 47) and rats (19).”
BackgroundA Critical Analysis of the Clinical Use of Incretin-Based Therapies
Nauck, M. A. (2013) · Diabetes Care · doi:10.2337/dc12-2504 · Cited by 205
“Clinically, the development of typical chronic pancreatitis diagnosed because of typicalmorphological findings and exocrine insufficiency leading to maldigestion, nutritional deficiencies, and weight loss over and above what is expected from continued stimulation of brain GLP-1 receptors (1,27) in patients treated wit…”
BackgroundMechanisms in bariatric surgery: Gut hormones, diabetes resolution, and weight loss
Holst, J. J., Madsbad, S., Bojsen-Møller, K. N., Svane, M. S., Jørgensen, N. B., Dirksen, C., & Martinussen, C. (2018) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2018.03.003 · Cited by 202
Self-citationSturis, J., Gotfredsen, C. F., Rømer, J., Rolin, B., Ribel, U., Brand, C. L., Wilken, M., Wassermann, K., Deacon, C. F., Carr, R. D., et al. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705397 · Cited by 202
“…including glucose-dependent stimulation of insulin secretion and inhibition of glucagon secretion (Gromada et al., 1998), inhibition of small bowel motility (Tolessa et al., 1998) and gastric emptying (Nauck et al., 1997), and reduction of appetite (Flint et al., 1998; Toft-Nielsen et al., 1999).”
BackgroundThe endocrinology of food intake
Begg, D. P., & Woods, S. C. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.136 · Cited by 201
Matthews, J. E., Stewart, M. W., De Boever, E. H., Dobbins, R. L., Hodge, R. J., Walker, S. E., Holland, M. C., Bush, M. A., & for the Albiglutide Study Group (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1518 · Cited by 198
Feinle, C., O'Donovan, D., Doran, S., Andrews, J. M., Wishart, J., Chapman, I., & Horowitz, M. (2003) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00512.2002 · Cited by 198
“GLP-1 has received considerable attention in recent years; it is known that, similar to CCK, GLP-1, when infused intravenously, is a potent regulator of gastric emptying and gastrointestinal motility (38, 43) and also inhibits food intake (12, 17).”
BackgroundPreproglucagon neurons project widely to autonomic control areas in the mouse brain
Llewellyn-Smith, I. J., Reimann, F., Gribble, F. M., & Trapp, S. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.02.023 · Cited by 194
“Both peripheral and central application of GLP-1 inhibits food intake and reduces blood glucose levels (Kreymann et al., 1987, Tang-Christensen et al., 1996, Turton et al., 1996, Flint et al., 1998, Abbott et al., 2005, Sandoval et al., 2008).”
BackgroundBreakfast Frequency and Quality May Affect Glycemia and Appetite in Adults and Children
Pereira, M. A., Erickson, E., McKee, P., Schrankler, K., Raatz, S. K., Lytle, L. A., & Pellegrini, A. D. (2011) · The Journal of Nutrition · doi:10.3945/jn.109.114405 · Cited by 193
Ford, H. E., Peters, V, Martin, N. M., Sleeth, M. L., Ghatei, M. A., Frost, G. S., & Bloom, S. R. (2011) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2010.291 · Cited by 195
“…food intake when administered to rodents (Batterham et al., 2002; Challis et al., 2003; Halatchev et al., 2004; Chelikani et al., 2005a, b, 2006; Talsania et al., 2005) and to humans (Flint et al., 1998; Gutzwiller et al., 1999; Batterham et al., 2002; Degen et al., 2005; Le Roux et al., 2006).”
BackgroundVerspohl, E. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.002 · Cited by 196
Flint, A., Gregersen, N. T., Gluud, L. L., Møller, B. K., Raben, A., Tetens, I., Verdich, C., & Astrup, A. (2007) · British Journal of Nutrition · doi:10.1017/s000711450768297x · Cited by 192
Self-citationPharmacotherapy of type 2 diabetes: An update
Upadhyay, J., Polyzos, S. A., Perakakis, N., Thakkar, B., Paschou, S. A., Katsiki, N., Underwood, P., Park, K.-H., Seufert, J., Kang, E. S., et al. (2018) · Metabolism · doi:10.1016/j.metabol.2017.08.010 · Cited by 187
Wettergren, A., Wøjdemann, M., & Holst, J. J. (1998) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1998.275.5.g984 · Cited by 197
Self-citationAntiobesity Pharmacotherapy: New Drugs and Emerging Targets
Kim, G. W., Lin, J. E., Blomain, E. S., & Waldman, S. A. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.204 · Cited by 191
Glycaemic control in type 2 diabetes: Targets and new therapies
Tahrani, A. A., Piya, M. K., Kennedy, A., & Barnett, A. H. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.11.001 · Cited by 190
Greig, N. H., Holloway, H. W., De Ore, K. A., Jani, D., Wang, Y., Zhou, J., Garant, M. J., & Egan, J. M. (1999) · Diabetologia · doi:10.1007/s001250051111 · Cited by 189
“As it has been proposed that GLP-1 is involved in the regulation of food intake [18] it can also be exendin4 is so involved.”
Incretin hormones and the satiation signal
Holst, J. J. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.208 · Cited by 188
Self-citationThe macronutrients, appetite, and energy intake
Carreiro, A. L., Dhillon, J., Gordon, S., Higgins, K. A., Jacobs, A. G., McArthur, B. M., Redan, B. W., Rivera, R. L., Schmidt, L. R., & Mattes, R. D. (2016) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-121415-112624 · Cited by 159
“In these experiments, administration of peptides reduced energy intake and/or increased feelings of satiety (18, 95, 227).”
Shao, N., Kuang, H. Y., Hao, M., Gao, X. Y., Lin, W. J., & Zou, W. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2561 · Cited by 185
“GLP-1 receptors are present in many organs in the body, such as the gastrointestinal tract and hypothalamus; thus, Exe inhibits gastric motility, retards gastric emptying and, through actions on the central nervous system, reduces appetite and induces satiety and fullness [30], acting as an indirect mechanism of weigh…”
BackgroundPowell, D. R., Smith, M., Greer, J., Harris, A., Zhao, S., DaCosta, C., Mseeh, F., Shadoan, M. K., Sands, A., Zambrowicz, B., et al. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.203364 · Cited by 184
“…challenge (Gorboulev et al., 2012), which suggests that LX4211 might lower postprandial GIP levels; this is important because decreased postprandial GIP levels may benefit patients with T2DM (Flint et al., 1998; Baggio and Drucker, 2007; Chia et al., 2009; Asmar et al., 2010; Reimann, 2010).”
BackgroundInfluentialJensen, L., Helleberg, H., Roffel, A., van Lier, J. J., Bjørnsdottir, I., Pedersen, P. J., Rowe, E., Derving Karsbøl, J., & Pedersen, M. L. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.03.020 · Cited by 182
“…(GLP-1), a gut-derived incretin hormone, stimulates insulin and inhibits glucagon secretion in a glucose-dependent manner, reduces appetite and energy intake, and also delays gastric emptying (Drucker and Nauck, 2006; Flint et al., 1998; Holst, 2007; Naslund et al., 1999; Willms et al., 1996).”
Glycaemic response to foods: Impact on satiety and long-term weight regulation
Bornet, F. R. J., Jardy-Gennetier, A.-E., Jacquet, N., & Stowell, J. (2007) · Appetite · doi:10.1016/j.appet.2007.04.006 · Cited by 182
Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes
Gautier, J.-F., Choukem, S.-P., & Girard, J. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)73397-4 · Cited by 183
“Importantly, the GLP-1 metabolite GLP-1 [9-36] amide that has no insulinotropic action, could also mediate myocardial glucose uptake, thus improving left ventricular performance in dogs with dilated cardiomyopathy [41].”
Power, O., Nongonierma, A. B., Jakeman, P., & FitzGerald, R. J. (2014) · Proceedings of the Nutrition Society · doi:10.1017/s0029665113003601 · Cited by 180
“1) include inhibition of gastric acid secretion((32)), decreased gastric emptying((33)), enhanced satiety and decreased food intake((34)).”
GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice
Hansotia, T., & Drucker, D. J. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.07.019 · Cited by 183
“[94] Flint A, Raben A, Astrup A, Holst JJ.”
BackgroundBush, M. A., Matthews, J. E., De Boever, E. H., Dobbins, R. L., Hodge, R. J., Walker, S. E., Holland, M. C., Gutierrez, M., & Stewart, M. W. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00992.x · Cited by 181
Horowitz, M., Flint, A., Jones, K. L., Hindsberger, C., Rasmussen, M. F., Kapitza, C., Doran, S., Jax, T., Zdravkovic, M., & Chapman, I. M. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.02.016 · Cited by 179
“Lowering of energy intake has been shown with exenatide [29], as well as native GLP-1 [1].”
BackgroundSelf-citationBody Weight, Anorexia, and Undernutrition in Older People
Soenen, S., & Chapman, I. M. (2013) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.02.004 · Cited by 178
Food Intake and Eating Behavior After Bariatric Surgery
Al-Najim, W., Docherty, N. G., & le Roux, C. W. (2018) · Physiological Reviews · doi:10.1152/physrev.00021.2017 · Cited by 173
Glucagon-like peptide 1 and its derivatives in the treatment of diabetes
Nauck, M. A., & Meier, J. J. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.07.014 · Cited by 180
Plamboeck, A., Veedfald, S., Deacon, C. F., Hartmann, B., Wettergren, A., Svendsen, L. B., Meisner, S., Hovendal, C., Vilsbøll, T., Knop, F. K., et al. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00035.2013 · Cited by 183
“1391 BaselineGLP-1, pM 18 (17) 23 (19) 0.”
BackgroundMethodResultInfluentialSelf-citationShort-Chain Fatty Acid Receptor and Its Contribution to Glucagon-Like Peptide-1 Release
Kaji, I., Karaki, S.-I., & Kuwahara, A. (2014) · Digestion · doi:10.1159/000356211 · Cited by 177
Harrold, J. A., Dovey, T. M., Blundell, J. E., & Halford, J. C. G. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.007 · Cited by 177
“The principle role of GLP-1 in appetite regulation is to release insulin and inhibit glucagon; however, it also delays gastric emptying (Näslund et al., 1999), inhibits food intake (Flint et al., 1998) and aids in the metabolism and absorption of specific macronutrients (Verdich et al., 2001).”
Nauck, M. A., Vilsbøll, T., Gallwitz, B., Garber, A., & Madsbad, S. (2009) · Diabetes Care · doi:10.2337/dc09-s315 · Cited by 169
“Additional activities of GLP-1 are the deceleration of gastric emptying (5), which slows the entry of nutrients into the circulation after meals, a reduction in appetite, and earlier induction of satiety (6), leading to weight reduction with chronic exposure (7).”
BackgroundKapitza, C., Nosek, L., Jensen, L., Hartvig, H., Jensen, C. B., & Flint, A. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.443 · Cited by 175
Self-citationKelly, A. S., Rudser, K. D., Nathan, B. M., Fox, C. K., Metzig, A. M., Coombes, B. J., Fitch, A. K., Bomberg, E. M., & Abuzzahab, M. J. (2013) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2013.1045 · Cited by 176
“Indeed, GLP-1 has been shown to be an endogenous satiety hormone.(16) In a recent feasibility trial,(17) we demonstrated that 3 months of exenatide treatment reduced BMI by approximately 5% and improved markers of insulin resistance and -cell function in adolescents with severe obesity who did not have diabetes.”
BackgroundLiraglutide: short‐lived effect on gastric emptying—long lasting effects on body weight
Jelsing, J., Vrang, N., Hansen, G., Raun, K., Tang‐Christensen, M., & Bjerre Knudsen, L. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01557.x · Cited by 155
“com with liraglutide or exenatide in both diabetic [8] and obese patients [9] in agreement with the first report of GLP-1-induced satiety and lowered energy intake [10].”
Vendrell, J., El Bekay, R., Peral, B., García-Fuentes, E., Megia, A., Macias-Gonzalez, M., Real, J. F., Jimenez-Gomez, Y., Escoté, X., Pachón, G., et al. (2011) · Endocrinology · doi:10.1210/en.2011-1070 · Cited by 173
Role of the glucagon-like-peptide-1 receptor in the control of energy balance
Hayes, M. R., De Jonghe, B. C., & Kanoski, S. E. (2010) · Physiology & Behavior · doi:10.1016/j.physbeh.2010.02.029 · Cited by 173
Appetite signaling: From gut peptides and enteric nerves to brain
Näslund, E., & Hellström, P. M. (2007) · Physiology & Behavior · doi:10.1016/j.physbeh.2007.05.017 · Cited by 173
“In humans, studies invariably report decreased food intake with ratings of reduced hunger and increased fullness following infusion of GLP-1, including studies in normal weight, diabetic and obese participants [41–48].”
Bowels control brain: gut hormones and obesity
Field, B. C. T., Chaudhri, O. B., & Bloom, S. R. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.93 · Cited by 172
Samra, R. A., & Anderson, G. H. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.4.972 · Cited by 169
de Boer, A., Ter Horst, G. J., & Lorist, M. M. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2012.08.002 · Cited by 166
The relationship between gut and adipose hormones, and reproduction
Comninos, A. N., Jayasena, C. N., & Dhillo, W. S. (2014) · Human Reproduction Update · doi:10.1093/humupd/dmt033 · Cited by 167
“GLP-1 can traverse the blood–brain barrier and peripheral GLP-1 infusions can therefore act in the brain to enhance satiety and reduce subsequent spontaneous food intake by 12% in healthy humans (Flint et al., 1998).”
The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent
Furman, B. L. (2012) · Toxicon · doi:10.1016/j.toxicon.2010.12.016 · Cited by 166
Kielgast, U., Krarup, T., Holst, J. J., & Madsbad, S. (2011) · Diabetes Care · doi:10.2337/dc11-0096 · Cited by 165
“However, GLP-1 also reduces appetite and spontaneous food intake (15,16).”
BackgroundSelf-citationBotfield, H. F., Uldall, M. S., Westgate, C. S. J., Mitchell, J. L., Hagen, S. M., Gonzalez, A. M., Hodson, D. J., Jensen, R. H., & Sinclair, A. J. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan0972 · Cited by 163
Effect of Glycemic Carbohydrates on Short-term Satiety and Food Intake
Anderson, G. H., & Woodend, D. (2003) · Nutrition Reviews · doi:10.1301/nr.2003.may.s17-s26 · Cited by 167
Wu, T., Zhao, B. R., Bound, M. J., Checklin, H. L., Bellon, M., Little, T. J., Young, R. L., Jones, K. L., Horowitz, M., & Rayner, C. K. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.021543 · Cited by 163
“Other actions of GLP-1 include slowing of gastric emptying (6) and reduction of appetite and energy intake (7).”
BackgroundGautier, J., Fetita, S., Sobngwi, E., & Salaün-Martin, C. (2005) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70190-8 · Cited by 163
Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors
Golightly, L. K., Drayna, C. C., & McDermott, M. T. (2012) · Clinical Pharmacokinetics · doi:10.1007/bf03261927 · Cited by 158
“When considered in light of several novel ancillary pharmacological actions of various incretin treatments that may be of additional therapeutic benefit,([12-30]) these effects commend GLP-1 augmentation as a highly attractive target in the management of diabetes.”
Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake
Cegla, J., Troke, R. C., Jones, B., Tharakan, G., Kenkre, J., McCullough, K. A., Lim, C. T., Parvizi, N., Hussein, M., Chambers, E. S., et al. (2014) · Diabetes · doi:10.2337/db14-0242 · Cited by 159
“The postprandial nausea seen in this study may instead be accounted for by a delay in gastric emptying triggered by glucagon and GLP-1 (31,32).”
BackgroundNäslund, E., King, N., Mansten, S., Adner, N., Holst, J. J., Gutniak, M., & Hellström, P. M. (2004) · British Journal of Nutrition · doi:10.1079/bjn20031064 · Cited by 160
“In human subjects, intravenous administration of GLP-1 has been shown to decrease food intake and hunger feelings in normal-weight subjects (Flint et al. 1998; Gutzwiller et al. 1999b), obese subjects (Näslund et al.”
InfluentialSelf-citationFeinle-Bisset, C., Patterson, M., Ghatei, M. A., Bloom, S. R., & Horowitz, M. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00220.2005 · Cited by 160
“We have now assayed the plasma samples from our previous study (11), in which we had evaluated the role of fat digestion on appetite and energy intake, antropyloroduodenal motility, and plasma CCK and GLP-1 concentrations.”
BackgroundInfluentialClinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide
Jalleh, R. J., Plummer, M. P., Marathe, C. S., Umapathysivam, M. M., Quast, D. R., Rayner, C. K., Jones, K. L., Wu, T., Horowitz, M., & Nauck, M. A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae719 · Cited by 157
“…on the initial observation that low-dose intracisternal administration of GLP-1 reduces food intake acutely in rodents (52, 53), and similar findings of exogenous IV administration of GLP-1 in healthy humans (54), GLP-1RAs have been found to reduce body weight substantially in both T2D and obesity.”
Ahrén, B., Atkin, S. L., Charpentier, G., Warren, M. L., Wilding, J. P. H., Birch, S., Holst, A. G., & Leiter, L. A. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13353 · Cited by 157
Iepsen, E. W., Zhang, J., Thomsen, H. S., Hansen, E. L., Hollensted, M., Madsbad, S., Hansen, T., Holst, J. J., Holm, J.-C., & Torekov, S. S. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.05.008 · Cited by 156
Self-citationCornell, S. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13230 · Cited by 156
Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes
Cervera, A., Wajcberg, E., Sriwijitkamol, A., Fernandez, M., Zuo, P., Triplitt, C., Musi, N., DeFronzo, R. A., & Cersosimo, E. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00030.2008 · Cited by 157
“This is not unexpected, since previous experiments with GLP-1 analogs (10, 22) and with exenatide (1) have shown a close relationship between the plasma GLP-1 level and delayed gastric emptying.”
ResultSaxena, A. R., Gorman, D. N., Esquejo, R. M., Bergman, A., Chidsey, K., Buckeridge, C., Griffith, D. A., & Kim, A. M. (2021) · Nature Medicine · doi:10.1038/s41591-021-01391-w · Cited by 156
Karasik, A., Aschner, P. J., Katzeff, H. L., Davies, M. J., & Stein, P. P. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x261069 · Cited by 163
de Fonseca, F. R., Navarro, M. A., Álvarez, E., Roncero, I., Chowen, J. A., Maestre, O., de Heras, R. G., Muñoz, R. M., Eng, J., & Blázquez, E. (2000) · Metabolism · doi:10.1053/meta.2000.6251 · Cited by 177
Therapy of type 2 diabetes mellitus based on the actions of glucagon‐like peptide‐1
Holst, J. J. (2002) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.328 · Cited by 155
“and reduce food intake in normal subjects [78,79].”
BackgroundSelf-citation
Metadata
- Authors
- Flint, A., Raben, A., Astrup, A., & Holst, J. J.
- Affiliations
- University of Copenhagen (DK)
- Venue
- Journal of Clinical Investigation
- Published
- 1998-02-01
- Volume
- 101
- Issue
- 3
- Pages
- 515-520
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC508592
- OpenAlex
- W1975756049
- Cited by
- 1,402
- References
- 40
- Citations by year
- 2026: 37 · 2025: 55 · 2024: 62 · 2023: 33 · 2022: 55 · 2021: 53 · 2020: 49 · 2019: 44 · 2018: 52 · 2017: 49 · 2016: 54 · 2015: 59 · 2014: 64 · 2013: 74 · 2012: 72
- FWCI
- 9.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Sundhed og Sygdom, Det Frie Forskningsråd
- Medical Research Council
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- glucagon-like peptide-1, satiety, appetite, energy intake, insulin, glucagon, blood glucose, appetite regulation, intravenous infusion
- MeSH terms
- Adult, Appetite, Appetite Depressants, Appetite Regulation, Blood Glucose, Energy Intake, Glucagon, Humans, Insulin, Male, Pain Measurement, Peptide Fragments, Protein Precursors, Satiation, Cross-Over Studies, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.